Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.
*Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older
**Infant study investigated patients aged 3 to <24 months
*Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older
**Infant study investigated patients aged 3 to <24 months
EUCRISA: A steroid-free option
For the treatment of mild-to-moderate atopic dermatitis in patients 3 months and older
Copay Cards
*Eligible patients pay as little as $10
* Eligibility required. Individual savings limited to $970 per tube or $3,880 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and Conditions apply
Order Samples
Register or sign in to check availability and request samples.
Infant Safety Study in patients 3 to <24 months of age
Learn more about a 28-day, single-arm, open-label safety study in 3 to <24 month old patients4
* Eligibility required. Individual savings limited to $970 per tube or $3,880 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and Conditions apply
“Sometimes I don’t even want to look at my own skin”
Nana is a dancer who has had mild-to-moderate atopic dermatitis for more than 30 years
Efficacy
EUCRISA has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up1,2
** This is an optional area where footnotes can live.
Safety Data
Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,3
** This is an optional area where footnotes can live.
Dosing
EUCRISA can be applied to the skin anywhere on the face and body1
For topical use only. Not for ophthalmic, oral or intravaginal use
** This is an optional area where footnotes can live.
- EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
- Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
- Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.
- Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
INDICATION
EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.